Mark Bleackley News Today

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.

Mark Bleackley, PhD, discusses the upcoming phase 2 trial of IHL-675A designed to explore arthritis treatment through dual-drug comparison, promising global expansion, and its impact on patients’ pain relief.

Results demonstrated IHL-675A was well-tolerated, with no concerning adverse events or serious adverse events reported.

MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 -- Incannex Healthcare Inc. , , a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine...

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive...

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has completed a constructive pre-Investigational New Drug (IND) application meeting with the US Food and Drug...

Public Announcement Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis ...

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) is preparing to advance its clinical trial assessing the treatment of rheumatoid arthritis to the second...

Date: July 13, 2023 Public Announcement Incannex Receives HREC Approval for Phase...